title: A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21.
abstract: Transgenic mice bearing the human poliovirus receptor (TgPVR) are less susceptible to oral inoculation, although they are susceptible to parenteral inoculation. We investigated the susceptibility of TgPVR 21 line [Arch. Virol. 130 (1994) 351] to poliovirus through various mucosal routes. Intranasal inoculation of a neurovirulent Mahoney strain (OM1) caused flaccid paralysis with viral replication in the central nervous system at a dose of 10(6) cell culture infectious dose (CCID50), in contrast, no paralysis following oral or intragastric inoculation of the same dose. Intranasal inoculation of a vaccine strain, Sabin 1, at 10(6) CCID50, resulted in no paralysis. Initial replication of poliovirus in the nasal cavity was confirmed by virus isolation and detection of negative-stranded replicative intermediates by RT-PCR and viral antigens using a high-sensitive immunohistochemistry and genome/transcripts by in situ hybridization. Poliovirus-specific IgG antibodies were elevated in the sera of surviving TgPVR21. This model can be used as a mucosal infection model and for differentiation of neurovirulent and attenuated poliovirus strains.
authors.affiliation: Department of Pathology, National Institute of Infectious Diseases, Tokyo 208-0011, Japan.
authors.forename: Noriyo
authors.initials: N
authors.lastname: Nagata
authors.forename: Takuya
authors.initials: T
authors.lastname: Iwasaki
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ami
authors.forename: Yuko
authors.initials: Y
authors.lastname: Sato
authors.forename: Ikuyoshi
authors.initials: I
authors.lastname: Hatano
authors.forename: Ayako
authors.initials: A
authors.lastname: Harashima
authors.forename: Yuriko
authors.initials: Y
authors.lastname: Suzaki
authors.forename: Takao
authors.initials: T
authors.lastname: Yoshii
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Hashikawa
authors.forename: Tetsutaro
authors.initials: T
authors.lastname: Sata
authors.forename: Yoshinobu
authors.initials: Y
authors.lastname: Horiuchi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Koike
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kurata
authors.forename: Akio
authors.initials: A
authors.lastname: Nomoto
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000032:analysis; D001921:Brain / Q000473:pathology / Q000821:virology; D002490:Central Nervous System / Q000473:pathology / Q000821:virology; D004195:Disease Models, Animal; D004198:Disease Susceptibility; D005260:Female; D007150:Immunohistochemistry; D008297:Male; D008565:Membrane Proteins; D051379:Mice; D008822:Mice, Transgenic; D009297:Nasal Mucosa / Q000473:pathology / Q000821:virology*; D010243:Paralysis / Q000473:pathology / Q000821:virology; D011051:Poliomyelitis / Q000097:blood / Q000473:pathology / Q000821:virology*; D017955:Poliovirus / Q000472:pathogenicity* / Q000502:physiology; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage; D011991:Receptors, Virus / Q000235:genetics*; D013116:Spinal Cord / Q000473:pathology / Q000821:virology; D013997:Time Factors
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D008565:Membrane Proteins; D011055:Poliovirus Vaccine, Oral; D011991:Receptors, Virus; C066100:poliovirus receptor